Oral antiplatelet efficacy and specificity of a novel nonpeptide platelet GPIIb/IIIa receptor antagonist, DMP 802

Journal of Cardiovascular Pharmacology

Volumn 32, Issue 2, 1998, Pages 169-176

  Mousa, Shaker A ^a   Olson, Richard E ^a   Bozarth, Jeffrey M ^a   Lorelli, William ^a   Forsythe, Mark S ^a   Racanelli, Adrienne ^a   Gibbs, Sandy ^a   Schlingman, Karen ^a   Bozarth, Tracy ^a   Kapil, Ram ^a   Wityak, John ^a   Sielecki, Thais M ^a   Wexler, Ruth R ^a   Thoolen, Martin J ^a   Slee, Andrew ^a   Reilly, Thomas M ^a   Anderson, Paul S ^a   Friedman, Paul A ^a  

^a DUPONT COMPANY   (United States)

Author keywords

Antiplatelet; Binding kinetics; DMP 802; GPIIb IIIa Receptors; Integrins; Oral antiplatelet

Indexed keywords

3 [[3 [4 (AMINOIMINOMETHYL)PHENYL] 4,5 DIHYDRO 5 ISOXAZOLYL]ACETAMIDO] N [(3,5 DIMETHYL 4 ISOXAZOLYL)SULFONYL]ALANINE; ACETYLSALICYLIC ACID; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FRADAFIBAN; HIRUDIN; LAMIFIBAN; TICLOPIDINE; TIROFIBAN; UNCLASSIFIED DRUG; XEMILOFIBAN;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; BINDING KINETICS; CONTROLLED STUDY; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SPECIFICITY; DRUG STRUCTURE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; THROMBOSIS;

ADMINISTRATION, ORAL; ANIMALS; BINDING, COMPETITIVE; BLOOD PLATELETS; CELL ADHESION; DOGS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBRONECTINS; HUMANS; INTEGRIN ALPHA4BETA1; INTEGRINS; ISOXAZOLES; MALE; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RATS; RECEPTORS, LYMPHOCYTE HOMING; RECEPTORS, VITRONECTIN; SULFONAMIDES; VITRONECTIN;

EID: 0031856930     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199808000-00001     Document Type: Article

References (28)

1. Hirsh PD, Hillis LD, Campbell WB, Firth BG, Willerson JT. Release of prostaglandins and thromboxane into the coronary circulation in patients with ischemic heart disease. N Engl J Med 1981; 304:685-91.
2. Rubenstein MD, Wall RT, Bain DS, Harrison DC. Platelet activation in clinical coronary artery disease and spasm. Am Heart J 1981;102:363-7.
3. Smitherman TC, Milam M, Woo J, Willerson JT, Frenkel EP. Elevated beta thromboglobulin in peripheral venous blood of patients with acute myocardial ischemia: direct evidence for enhanced platelet reactivity in vivo. Am J Cardiol 1981;48:395-402.
4. Fitzgerald DJ, Roy L, Catella F, Fitzgerald GA. Platelet activation in unstable coronary disease. N Engl J Med 1986;315:983-9.
5. Fuster V, Steele PM, Chesebro JH. Role of platelets and thrombosis in coronary atherosclerotic disease and sudden death. J Am Coll Cardiol 1985;5:175B-84B.
6. Willerson JT, Golino P, Eidt J, Campbell WB, Buja LM. Specific platelet mediators and unstable coronary artery lesions: experimental evidence and potential clinical implications. Circulation 1989;80:198-205.
7. Davies MJ, Thomas AC. Plaque fissuring: the cause of acute myocardial infarction, sudden ischemic death, and crescendo angina. Br Heart J 1985;53:363-73.
8. Hamm CW, Bliefield W, Kupper W, Lorenz RL, Weber PC, Wober W. Biochemical evidence of platelet activation in patients with persistent unstable angina. J Am Coll Cardiol 1987;10:998-1004.
9. Ashby B, Daniel JL, Smith JB. Mechanisms of platelet activation and inhibition. Platelet Health Dis 1990;4(1):1-26.
10. Kruithof EKO, Tran-Thang C, Bachman F. Studies on the release of a plasminogen activator inhibitor by human platelets. Thromb Haemost 1986;55:201-5.
11. Pytela R, Pierschbacher MS, Ginsberg MH, Plow EF, Ruoslahti E. Platelet membrane glycoprotein IIb/IIIa: member of a family of RGD specific adhesion receptors. Science 1986;231:1559-62.
12. Philips DR, Charo IF, Scarborough RM. GPIIb/IIIa: the responsive integrin. Cell 1991;65:359-62.
13. D'Souza SE, Ginsberg MH, Burke TA, Plow FF. The ligand binding site of the platelet integrin receptor GPIIb-IIIa is proximal to the second calcium binding domain of Its a subunit. J Biol Chem 1990;265:3440-6.
14. Cook NS, Kottirsch G, Zerwes H-G. Platelet glycoprotein IIb/IIIa antagonists. Drugs Future 1994;19:135-59.
15. Nichols AJ, Ruffolo RR, Huffman WF, Poste G, Samanen J. Development of GPIIb/IIIa antagonists as antithrombotic drugs. Trends Pharmacol Sci 1992;13(11):413-7.
16. Yasuda T, Gold HK, Yaoita H, Leinbach RC, et al. Comparison effects of aspirin, a synthetic thrombin inhibitor and a monoclonal antiplatelet glycoprotein IIb/IIIa antibody on coronary artery reperfusion, reocclusion and bleeding with recombinant tissue-type plasminogen activator in a canine preparation. J Am Coll Cardiol 1990;16:714-22.
17. Coller BS, Folts JD, Scudder LE, Smith SR. Antithrombotic effect of a monoclonal antibody to the platelet glycoprotein IIb/IIIa receptor in an experimental animal model. Blood 1986;68:783-6.
18. Topol EJ. Novel antithrombotic approaches to coronary artery diseases. Am J Cardiol 1995;75(6):27b-33b.
19. Mousa SA, Topol E. Novel antiplatelet therapies: recent advances in the development of platelet GPIIb/IIIa receptor antagonists. Current review of interventional cardiology, Third edition. Patrick W. Serruys and David Holmes, eds. Philadelphia: Current Medicine, 1997;13:114-29.
20. Tcheng JE, Harrington RA, Kottke-Marchant K, et al. Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker, Integrelin in elective coronary intervention: IMPACT investigators. Circulation 1995;91 (8):215-7.
21. Kottke-Marchant K, Simpfendorfer C, Lowrie M, Burns D, Anders RJ. Sustained but variable inhibition of platelet aggregation with xemilofiban, an oral GPIIb/IIIa receptor antagonist, in patients with unstable angina. Circulation 1995;92(8 suppl):I-488.
22. Narjes H, Weisenberger H, Muller TH, Deichsel G, Krause L. Tolerability and platelet fibrinogen receptor occupancy (FRO) after oral treatment with BIBU 104 in healthy volunteers [Abstract]. Thromb Haemost 1995;73(6):1315-592.
23. Mousa S, Bozarth J, Forsythe M, et al. Antiplatelet, antithrombotic efficacy of DMP 728, a novel platelet GPIIb/IIIa receptor antagonist. Circulation 1994;89:3-12.
24. Mousa SM, Forsythe Wm Lorelli J, et al. Novel nonpeptide glycoprotein IIb/IIIa receptor antagonist, DMP 754: receptor binding affinity and specificity. Coron Artery Dis 1996;7(10):767-74.
25. Bennet JS, Vilaire GO. Exposure of platelet fibrinogen receptors by ADP and epinephrine. J Clin Invest 1979;64:1393-401.
26. Kapil R, Emm T, Mousa SA, Padovani P, Quon C, Lam G. Biological matrix-dependent pharmacokinetic and pharmacodynamic parameters of a novel antiplatelet agent. XU063, in beagle dogs. Thromb Res 1997;86(3):221-32.
27. Peerlinck K, De Lepeleire I, Goldberg M, et al. MK383 (L-700462), a selective nonpeptide platelet glycoprotein IIb/IIIa antagonist, is active in man. Circulation 1993:88(4 Pt 1):1512-7.
28. Topol EJ, Plow EF. Clinical trials of platelet receptor inhibitors. Thromb Haemost 1993;70:94-8.